In this study, we found that the MM patients’ serum IL-17A level was independently associated with bone lesions and fractures, and the high level of serum IL-17A (>0.1 pg/ml) was related to severe baseline bone disease, which was consistent with the results of previous clinical and experimental research performed by Noonan et al. Here, IL17A is linked to Miyoshi myopathy.